A method to determine stroke trial success using multidimensional pooled control functions

Stroke

Volumn 40, Issue 5, 2009, Pages 1803-1810

  Mandava, Pitchaiah ^a   Kent, Thomas A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acute stroke; Cerebrovascular accident; Clinical trials; Drug trials; Outcomes

Indexed keywords

ABCIXIMAB; ALTEPLASE; CITICOLINE; DISUFENTON SODIUM; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; NALMEFENE; PLACEBO; PROUROKINASE; UROKINASE;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FUNCTIONAL ASSESSMENT; HUMAN; MORTALITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; ALGORITHM; EMERGENCY HEALTH SERVICE; FACTUAL DATABASE; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; STATISTICAL ANALYSIS; STATISTICAL MODEL; STROKE;

AGED; ALGORITHMS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STROKE; TREATMENT OUTCOME;

EID: 65549170306     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.532820     Document Type: Article

References (51)

1. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th century. Stroke. 2001;32: 1349-1359.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
3. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke. 2005;36:880-890.
4. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
5. Adams HP, Effron MB, Torner J, Davalos A, Frayne J, Teal P, Leclerc J, Oemer B, Padgett L, Barnathan ES, Hacke W; AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international Phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39:87-99.
6. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571.
7. Labiche LA, Grotta JC. Pharmacologic modification of acute cerebral ischemia. In: Mohr JC, Choi DW, Grotta JC, Weir B, Wolff PA, eds. Stroke Pathophysiology, Diagnosis and Management, IV ed. New York: Elsevier; 2004:1025-1058.
8. Grotta JC, Labiche LA. Combination of thrombolytic therapy with neu-roprotectants. In: Lyden PD, ed. Thrombolytic Therapy for Acute Stroke, II ed. Totowa, NJ: Humana Press; 2005:77-93.
9. Weimar C, Konig IR, Kraywinkel K, Ziegler A, Diener HC; German Stroke Study Collaboration. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. Stroke. 2004;35:158-162.
10. Mandava P, Kent TA. Intra-arterial therapies for acute ischemic stroke. Neurology. 2007;68:2132-2139.
11. Uchino K, Billheimer D, Cramer SC. Entry criteria and baseline characteristics predict outcome in acute stroke trials. Stroke. 2001;32:909-916.
12. Zar JH. Biostatistical Analysis, III ed. Upper Saddle River, NJ: Prentice-Hall; 1996:282-283.
13. Matlab Optimization Toolbox. Users Guide. Version 2. Natick, MA: The Mathworks Inc; 2000.
14. Beers KJ. Numerical Methods for Chemical Engineering. Applications in Matlab. Cambridge, UK: Cambridge University Press; 2007:81-85, 225-230.
15. Pedhazhur EJ, Pedhazur LS. Measurement, design, and analysis: an integrated approach. Hillsdale, NJ: Lawrence Erlbaum Associates; 1991: 398-399.
16. NIST/SEMATECH e-Handbook ofStatistical Methods. Available at: www. itl.nist.gov/div898/handbook/Chapter 4.1.3.2. Accessed February 1, 2008.
17. Bates DM, Watts DW. Nonlinear Regression Analysis and Its Applications. New York: Wiley; 1988:6-13.
18. Dolan KD, Yang L, Trampel CP. Nonlinear regression technique to estimate kinetic parameters and confidence intervals in unsteady-state conduction-heated foods. J Food Eng. 2007;80:581-593.
19. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke. 1994;25:418-423.
20. Rudolf J; HES in Acute Stroke Study Group. Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase II safety study. Cerebrovasc Dis. 2002;14:33-41.
21. Lamonte MP, Nash ML, Wang DZ, Woolfenden AR, Schultz J, Hursting MJ, Brown PM; ARGIS-1 Investigators. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke. 2004;35:1677-1682.
22. The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke. 1996;27:1453-1458.
23. Lampl Y, Zivin JA, Fisher M, Lew R, Welin L, Dahlof B, Borenstein P, Andersson B, Perez J, Caparo C, Ilic S, Oron U. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke. 2007; 38:1843-1849.
24. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282: 2019-2026.
25. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM; EPITHET Investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008; 7:299-309.
26. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
27. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0-to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study: Thrombolytic Therapy in Acute Ischemic Stroke Study investigators. Stroke. 2000;31:811-816.
28. Montaner J, Chacon P, Krupinski J, Rubio F, Millan M, Molina CA, Hereu P, Quintana M, Alvarez-Sabin J. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol. 2008;15:82-90.
29. Sacco RL, DeRosa JT, Haley EC, Levin B, Ordronneay P, Phillips SJ, Rundek T, Snipes RG, Thompson JL; Glycine Antagonist in Neuropro-tection Americas Investigators. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA. 2001;285:1719-1728.
30. Lyden P, Jacoby M, Schim J, Albers G, Mazzeo P, Ashwood T, Nordlund A, Odergren T. The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results. Neurology. 2001;57:1199-1205.
31. Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology. 2001;57:1428-1434.
32. Clark WM, Coull BM, Karukin M, Hendin B, Kelley R, Rosing H, Zachariah S, Winograd M, Raps E, Walshe T, Singer S, Mettinger KL. Randomized trial of cervene, a kappa receptor-selective opioid antagonist, in acute ischemic stroke. J Stroke Cerebrovasc Dis. 1996;6:35-40.
33. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE; Citicholine Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 2001;57:1595-1602.
34. Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemeto S, Miyamoto S, Sasaki M, Inoue T; MELT Japan Study Group. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke. 2007;38:2633-2639.
35. NINDS t-PA Stroke Study Data Set (on CD-ROM). Available at: www. ntis.gov. Data processed in Matlab. Accessed February 1, 2008.
36. Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, Wechsler L, Ashwood T, Claeson L, Odergren T, Salazar-Grueso E; CLASS-I/H/T Investigators. Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke. 2002;33:122-128.
37. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saggur M, Demchuk AM, Moye LA, Hill MD, Wojner AJ; CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004; 351:2170-2178.
38. Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke. 2005;36:2415-2420.
39. Furlan AJ, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
40. Eggers J, Konig IR, Koch B, Handler G, Seidel G. Sonothrombolysis with transcranial color-coded sonography and recombinant tissue-type plas-minogen activator in acute middle cerebral artery main stem occlusion: results from a randomized study. Stroke. 2008;39:1470-1475.
41. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998; 29:4-11.
42. Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, Christianson TJ. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke. 2004;35:2418-2424.
43. Grotta JC. The NINDS Stroke Study Group Response. BMJ. 2002. Available at: www.bmj.com/cgi/eletters/324/7339/723. Accessed February 1, 2008.
44. Ezuri M, Kagawa S. Selective and superselective infusion of urokinase for embolic stroke. Surg Neurol. 1992;38:353-358.
45. Fischer U, Arnold M, Nedeltchev K, Brekenfeld C. NIHSS score and arteriographic findings in acute ischemic stroke. Stroke. 2005;36: 2121-2125.
46. Ginsberg MD. Life after Cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. Stroke. 2007;38:1967-1972.
47. Hess DC. NXY-059: a hopeful sign in the treatment of stroke. Stroke. 2006;37:2649-2650.
48. Adams HP, Leclerc JR, Bluhmki E, Clark W, Hansen MD, Hacke W. Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis. 2004;18:124-129.
49. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38:3055-3062.
50. Fisher M, Hanley DF, Howard G, Jauch EC, Warach S; STAIR Group. Recommendations from the STAIR V Meeting on Acute Stroke Trials, Technology and Outcomes. Stroke. 2007;38:245-248.
51. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis versus dichotomization of the modified Rankin Scale outcome scores in the NINDS and ECASS-II trials. Stroke. 2007;38:3205-3212.